Accounts Receivable, after Allowance for Credit Loss, Current of SOLENO THERAPEUTICS INC from 31 Dec 2013 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
SOLENO THERAPEUTICS INC quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD history and change rate from 31 Dec 2013 to 31 Dec 2025.
  • SOLENO THERAPEUTICS INC Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending 31 Dec 2025 was $28,208,000.
Source SEC data
View on sec.gov
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Change (%)

SOLENO THERAPEUTICS INC Quarterly Accounts Receivable, after Allowance for Credit Loss, Current (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $28,208,000 31 Dec 2025 10-K 25 Feb 2026 2025 FY
Q3 2025 $25,506,000 30 Sep 2025 10-Q 04 Nov 2025 2025 Q3
Q2 2025 $24,624,000 30 Jun 2025 10-Q 06 Aug 2025 2025 Q2
Q4 2018 $0 31 Dec 2018 10-K 20 Mar 2019 2018 FY
Q3 2017 $0 -$137,000 -100% 30 Sep 2017 10-Q 14 Nov 2017 2017 Q3
Q2 2017 $3,000 -$285,000 -99% 30 Jun 2017 10-Q 11 Aug 2017 2017 Q2
Q1 2017 $110,000 -$77,000 -41% 31 Mar 2017 10-Q 11 May 2017 2017 Q1
Q4 2016 $3,000 -$153,127 -98% 31 Dec 2016 10-Q 14 Nov 2017 2017 Q3
Q3 2016 $137,000 +$43,000 +46% 30 Sep 2016 10-Q 14 Nov 2016 2016 Q3
Q2 2016 $288,000 +$276,000 +2300% 30 Jun 2016 10-Q 12 Aug 2016 2016 Q2
Q1 2016 $187,000 +$179,000 +2238% 31 Mar 2016 10-Q 09 Aug 2016 2016 Q1
Q4 2015 $156,127 +$156,127 31 Dec 2015 10-K 15 Mar 2017 2016 FY
Q3 2015 $94,000 +$57,000 +154% 30 Sep 2015 10-Q 12 Nov 2015 2015 Q3
Q2 2015 $12,000 30 Jun 2015 10-Q 10 Aug 2015 2015 Q2
Q1 2015 $8,000 31 Mar 2015 10-Q 04 May 2015 2015 Q1
Q4 2014 $0 -$149,605 -100% 31 Dec 2014 10-K 25 Mar 2016 2015 FY
Q3 2014 $37,000 30 Sep 2014 10-Q 18 Dec 2014 2014 Q3
Q4 2013 $149,605 31 Dec 2013 10-K 13 Mar 2015 2014 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.